Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 99mTc-HMPAO brain SPECT in the monitoring of cerebral vasculitis therapy
Journal Information
Vol. 37. Issue 4.
Pages 211-217 (July - August 2018)
Share
Share
Download PDF
More article options
Visits
6
Vol. 37. Issue 4.
Pages 211-217 (July - August 2018)
Original Article
99mTc-HMPAO brain SPECT in the monitoring of cerebral vasculitis therapy
99mTc-HMPAO SPECT cerebral en la monitorización de la terapia de vasculitis
Visits
6
Viviana Frantellizzia,c,
Corresponding author
, Manuela Morrealeb, Mariano Ponticoa, Ada Franciab, Francesco Maria Drudia, Alessio Farcomenid, Mauro Liberatorea
a Department of Radiological, Oncological and Anatomo-Pathological Sciences, “Sapienza” University of Rome, Rome, Italy
b Department of Neurology and Psychiatry, “Sapienza” University of Rome, Rome, Italy
c PhD Program: Angio-Cardio-Thoracic Pathophisiology and Imaging, “Sapienza” University of Rome, Rome, Italy
d Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Estimated changes of percentage of maximum count rate registered on the encephalon at each time point, by SPECT and within the whole group of studied vasculitis (n=50).
Table 2. Estimated changes of percentage of maximum count rate registered on the encephalon at each time point, by SPECT in the SLE patients (n=18).
Table 3. Estimated changes of percentage of maximum count rate registered on the encephalon at each time point, by SPECT in the UV patients (n=22).
Show moreShow less
Abstract
Objective

The central nervous system (CNS) may be involved in a variety of inflammatory diseases of the blood vessels, generally known as vasculitis. The clinical diagnosis of such involvement in early stages is difficult, since a mild cognitive impairment can be the only symptom. It was hypothesized that brain-perfusion SPECT would be able to reveal CNS involvement and to monitor the course of the disease. The purpose of this study was assess if and when an improvement of cerebral perfusion can be registered by SPECT during the follow-up of these diseases.

Material and methods

Eighteen patients affected by Systemic Lupus Erythematosus (SLE), 22 by undifferentiated vasculitis (UV), 5 by Behcet's disease (BD) and 5 by primary Sjogren's Syndrome (pSS) were enrolled in this prospective study. A 99mTc-HMPAO brain perfusion SPECT was performed before the treatment and was repeated during the follow-up at different time intervals. Image analysis was performed on 10 cerebral areas using a specific software.

Results

In the SLE patients, no significant improvement of brain perfusion was found. On the contrary, in the UV the cerebral uptake of the tracer significantly improved from the twenty-fourth month (18/22 patients). Patients with BD showed an improvement of scintigraphic findings (5/5 patients), while a similar result was obtained only in 2 of the patients with pSS.

Conclusions

In conclusion, brain SPECT seems to be able to monitor the disease in UV, indicating the moment when an improvement of the cerebral perfusion is achieved. In SLE patients this scintigraphic technique did not show a significant improvement in CNS perfusion.

Keywords:
Vasculitis
Brain perfusion
SPECT
Monitoring of therapy
Resumen
Objetivo

El sistema nervioso central (SNC) puede estar afectado en una variedad de enfermedades inflamatorias de los vasos sanguíneos, generalmente conocidas como vasculitis. El diagnóstico clínico de dicha afectación en etapas tempranas es difícil, ya que un leve deterioro cognitivo puede ser el único síntoma. Se planteó la hipótesis de que la SPECT de perfusion cerebral podría mostrar la afectación del SNC y podría servir para controlar el curso de la enfermedad. El propósito de este estudio fue evaluar si y cuándo una mejora de la perfusión cerebral puede ser registrada por SPECT durante el seguimiento de estas enfermedades.

Material y métodos

Dieciocho pacientes afectados por Lupus eritematoso sistémico (LES), 22 por vasculitis indiferenciada (UV), 5 por la enfermedad de Behcet (BD) y 5 por el síndrome de Sjogren Primario (pSS) se incluyeron en este estudio prospectivo. Se realizó una SPECT de perfusión cerebral con 99mTc-HMPAO antes del tratamiento, y se repitió durante el seguimiento a diferentes intervalos de tiempo. El análisis de imagen se realizó en 10 áreas cerebrales utilizando un software específico.

Resultados

En los pacientes con LES no se encontró una mejora significativa de la perfusión cerebral. Por el contrario, en la UV la captación cerebral del trazador comenzó a mejorar significativamente desde el vigésimo cuarto mes (18/22 pacientes). Los pacientes con BD mostraron una mejora de los hallazgos gammagráficos (5/5 pacientes), mientras que sólo se obtuvo un resultado similar en dos de los pacientes con pSS.

Conclusiones

En conclusión, el SPECT cerebral parece ser capaz de monitorizar la enfermedad en UV, evaluando cuándo se puede registrar una mejoría de la perfusión cerebral. En los pacientes con LES, esta técnica gammagráfica no ha encontrado una mejoría significativa en la perfusión del SNC.

Palabras clave:
Vasculitis
Perfusión cerebral
SPECT
Seguimiento de la terapia

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos